Raily Aesthetic Medicine FY26 interim profit turns to RMB 3.51 million; revenue rises 35.7% to RMB 114.78 million

• Raily Aesthetic Medicine returned to profit, posting RMB 3.51 million profit, versus a RMB 9.46 million loss a year earlier.
• Revenue rose 35.7% to RMB 114.78 million, driven by higher sales of aesthetic medical device products.
• Profit attributable to owners was RMB 4.1 million, swinging from a RMB 7.57 million loss; basic EPS was RMB 0.74 cents.
• Aesthetic medical device products revenue more than doubled to RMB 36.5 million; aesthetic medical services revenue increased 4.5% to RMB 78.28 million.
• Active clients climbed 9.9% to about 26,600; Hong Kong clinic revenue was RMB 8.5 million following a January investment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Raily Aesthetic Medicine International Holdings Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260828-12306334), on August 28, 2026, and is solely responsible for the information contained therein.